68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT in Metastatic Papillary Renal Cell Cancer.

ABSTRACT Papillary renal cell cancer is a rare malignancy with limited treatment options in the advanced stage of the disease. We present the case of a 62-year-old man with progressive left-sided papillary renal cell carcinoma who underwent 68Ga-FAPI (fibroblast activated protein inhibitor)-04 and 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT demonstrated variable FAP expression in all metastatic lesions detected by 18F-FDG PET/CT, including multiple lymph nodes, bone, and thyroid. This case highlights that FAP-targeted imaging can be a promising modality for diagnostic and theranostic use in papillary renal cell carcinoma.

[1]  Wenlan Zhou,et al.  Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging. , 2022, Clinical nuclear medicine.

[2]  R. Campi,et al.  PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature , 2022, Journal of clinical medicine.

[3]  M. Stöckle,et al.  Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort , 2022, Journal of Cancer.

[4]  S. Hancock,et al.  Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  R. Subramaniam,et al.  Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management , 2021, Frontiers in Oncology.

[6]  O. Sanli,et al.  68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes. , 2021, Clinical nuclear medicine.

[7]  Z. Özkan,et al.  Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04 , 2021, Clinical nuclear medicine.

[8]  Y. Şanlı,et al.  Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma. , 2021, Clinical nuclear medicine.

[9]  Dachun Zhao,et al.  Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma , 2021, Cancer Imaging.

[10]  Liang Zhao,et al.  68Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell Carcinoma. , 2020, Clinical nuclear medicine.

[11]  Xiaorong Yang,et al.  A comparison of the prognosis of papillary and clear cell renal cell carcinoma , 2019, Medicine.

[12]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[13]  U. Tateishi,et al.  Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course , 2012, BMC Cancer.

[14]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.